REST (RE1-silencing transcription factor)

Faronato, Monica; Coulson, Judy M.

doi:10.4267/2042/44968

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we mentioned, our results may have been influenced by the presence of various REST isoforms in the blood 29 ; the ELISA kit we used allows the detection of two out of four known isoforms (isoforms 1 and 4). Furthermore, REST levels in the bloodstream may be variable, as it has been reported for other molecules like β-amyloid which fluctuates over the day 30 , considering that REST activity varies from one peripheral tissue to another, up-and downregulated genes in different organs to maintain structural and physiological functions 31,32 .…”

Section: A B C Dmentioning

confidence: 99%

Serum Repressor Element-1 Silencing Transcription Factor Levels in Alzheimer's Patients from a National Institute of Health in Mexico City, Elderly and Young Controls

Ramírez-Cuapio

Torres-Ramos

Orozco-Ibarra³

et al. 2021

RIC

View full text Add to dashboard Cite

Background: Decreased levels of repressor element-1 silencing transcription (REST) factor in the brain, plasma, and neuronderived exosomes are associated with Alzheimer's disease (AD). Objective: The objective of the study was to test the viability of serum REST as a possible blood-based biomarker for AD, comparing serum REST levels in AD patients from a National Institute of Health in Mexico City (with different levels of severity and comorbidities), with elderly controls (EC) and young controls (YC). Methods: We used an enzyme-linked immunosorbent assay to determine serum REST levels in AD patients (n = 28), EC (n = 19), and YC (n = 24); the AD patients were classified by dementia severity and comorbidities (depression and microangiopathy) using clinimetric tests and magnetic resonance imaging. Results: Mean serum REST levels did not differ between AD patients, EC, and YC. The severity of AD and the presence of depression or microangiopathy were not associated with serum REST levels. Conclusion: Our results differ from previously published patterns found for plasma and cerebral REST levels. Free serum REST levels may not be a viable AD blood-based biomarker. (REV INVEST CLIN.

show abstract